Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gynaecological cancers 1

813MO - Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial


18 Sep 2020


Mini Oral - Gynaecological cancers 1


Cytotoxic Therapy

Tumour Site

Ovarian Cancer


Jean-Sebastien Frenel


Annals of Oncology (2020) 31 (suppl_4): S551-S589. 10.1016/annonc/annonc276


J. Frenel1, J. Kim2, D. Berton-Rigaud1, R. Asher3, L. Vidal4, P. Pautier5, J.A. Ledermann6, R.T. Penson7, A.M. Oza8, J. Korach9, T. Huzarski10, S. Pignata11, N. Colombo12, T. Park-Simon13, K. Tamura14, G.S. Sonke15, A. Freimund16, C.K. Lee17, E. Pujade-Lauraine18

Author affiliations

  • 1 Centre René Gauducheau, GINECO & Institut de Cancerologie de l'Ouest, 44805 - Saint-Herblain/FR
  • 2 Department Of Obstetrics And Gynecology, Seoul National University College of Medicine, Seoul/KP
  • 3 The University Of Sydney, NHMRC Clinical Trials Centre, 1450 - Sydney/AU
  • 4 Medical Oncology, GEICO & H Clínic de Barcelona, Barcelona/ES
  • 5 Medical Oncology, GINECO & Gustave Roussy Cancer Center, 94805 - Villejuif/FR
  • 6 Department Of Oncology, NCRI & University College London, WC1E6BT - London/GB
  • 7 Medical Oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 8 Medical Oncology And Hematology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 9 Department Of Gynecologic Oncology, ISGO & Chaim Sheba Medical Center, 52621 - Tel Aviv/IL
  • 10 Genetics And Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin/PL
  • 11 Department Of Urology And Gynecology, MITO & Istituto Nazionale Tumori IRCCS Fondazione “G. Pascale”, 80131 - Napoli/IT
  • 12 Gynecologic Oncology Dept., MaNGO & European Institute of Oncology and University of Milan-Bicocca, 20141 - Milano/IT
  • 13 Gynecologic Oncology, AGO & Hannover Medical School, 30625 - Hannover/DE
  • 14 Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 15 Department Of Medical Oncology, DGOG & The Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 16 Medical Oncology, Peter MacCallum Cancer Centre, Melbourne/AU
  • 17 Cancer Care Centre, St George Public Hospital, 2217 - Sydney/AU
  • 18 Medical Oncology, ARCAGY-GINECO, Paris/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 813MO


SOLO2 (ENGOT Ov-21; NCT01874353) demonstrated that maintenance olaparib (O) in patients (pts) with platinum-sensitive relapsed EOC and a BRCA1/2 mutation led to clinically significant survival benefit. We report on the efficacy of subsequent chemotherapy at the time of disease progression.


First subsequent treatment was analysed in pts who progressed according to RECIST1.1 in the O and placebo (P) arms. We conducted a post-hoc analysis of time to second progression (TTSP) calculated from the date of RECIST progression after O maintenance to next progression or death as a surrogate of first post-olaparib treatment progression-free survival.


106/195 (54%) and 80/99 (81%) pts had a RECIST progression in the O and P arms respectively. Pt baseline demographics were balanced between both arms. Overall, 161/186 (87%) pts received a first subsequent therapy, including a chemotherapy in 150/161 (93%) and a PARP inhibitor in 29/161 (18%, all in the P arm). In the P arm, 33/75 (44%) and 42/75 (56%) pts received a non-platinum and a platinum-based chemotherapy respectively vs 32/86 (37%) and 54/86 (63%) in the O arm. Overall, in pts receiving subsequent treatment, TTSP was longer in the placebo compared to the O arm: 11.1 vs 7 months (HR 1.93; 95% CI [1.35-2.76]). TTSP was 14.3 vs 7m with platinum-based chemotherapy and 8.3 vs 5.5m with non-platinum chemotherapy in the P and O arm respectively.


In this SOLO2 post-hoc comparison, some degree of resistance to standard subsequent platinum and non-platinum chemotherapy is noted in the O arm. However, the TTSP reduction being not at the expense of overall survival, it suggests that the earlier use of O remains optimal in this population. The best post O management should be studied in prospective manner.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study





J-S. Frenel: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: BioCad; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis pharma SAS; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer Pharmaceuticals Israel; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Tesaro. D. Berton-Rigaud: Advisory/Consultancy, Board: AstraZeneca; Advisory/Consultancy, Board: Tesaro; Travel/Accommodation/Expenses, ESMO ASCO: Pfizer; Travel/Accommodation/Expenses, ESMO ASCO: PharmaMar. L. Vidal: Full/Part-time employment: Syneos Health ( CRO). P. Pautier: Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Tesaro; Advisory/Consultancy: GSK. J.A. Ledermann: Honoraria (self), Advisory/Consultancy: AstraZeneca/MedImmune; Advisory/Consultancy: Artios; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Clovis Oncology; Advisory/Consultancy: Cristal Therapeutics; Advisory/Consultancy: Eisai; Advisory/Consultancy: Merck; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Tesaro; Speaker Bureau/Expert testimony: Tesaro/GSK; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): MSD Oncology. R.T. Penson: Honoraria (self), Advisory/Consultancy, Other Relationship: AbbVie; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Clovis Oncology; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Eisai Inc; Honoraria (self): Genentech/Roche; Honoraria (self), Advisory/Consultancy: Janssen Oncology (J & J); Honoraria (self), Advisory/Consultancy: Mersana Therapeutics, Inc.; Honoraria (self): Newlink Genetics; Honoraria (self), Advisory/Consultancy: Sutro Biopharma; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Tesaro Inc.; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Vascular Biogenics Ltd; Advisory/Consultancy: Amgen; Advisory/Consultancy: Baxalta; Advisory/Consultancy: Care4ward; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Genentech; Advisory/Consultancy: Merck; Research grant/Funding (institution): Array BioPharma; Research grant/Funding (institution): Cerulean Pharma; Research grant/Funding (institution): Regeneron; Research grant/Funding (institution): Sanofi; Licensing/Royalties: Blackwell Publishing; Licensing/Royalties: BMJ; Licensing/Royalties: UpToDate. A.M. Oza: Honoraria (self): Intas; Advisory/Consultancy: Immunogen; Advisory/Consultancy: Merck KGaA; Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Research grant/Funding (institution): Immunovaccine; Non-remunerated activity/ies, Other Relationship: Clovis Oncology; Non-remunerated activity/ies, Other Relationship: Tesaro. J. Korach: Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: MSD Oncology. S. Pignata: Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self): GSK; Honoraria (self): Clovis; Honoraria (self): PharmaMar; Honoraria (self): Incyte. N. Colombo: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: PharmaMar; Honoraria (self), Advisory/Consultancy: Roche/Genentech; Honoraria (self), Advisory/Consultancy: Tesaro; Advisory/Consultancy: BioCad; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: GSK; Advisory/Consultancy: MSD Oncology; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Takeda. T-W. Park-Simon: Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Tesaro; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: Lilly; Advisory/Consultancy: Daichi; Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy: MS. K. Tamura: Research grant/Funding (self), Research grant/Funding (institution): Pfizer; Research grant/Funding (self): Daiichi Sankyo; Research grant/Funding (self): Eli Lilly; Research grant/Funding (self): MSD; Research grant/Funding (self): Chugai; Research grant/Funding (self): AstraZeneca. G.S. Sonke: Advisory/Consultancy, Research grant/Funding (institution): Novartis; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Merck Sharp & Dohme; Research grant/Funding (institution): Roche. A. Freimund: Licensing/Royalties, as CPI of the clinical trial, PRECISE, that is receiving study drug and part study funding: BeiGene Pharmaceuticals. C.K. Lee: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Takeda. E. Pujade-Lauraine: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self): GSK; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Tesaro; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Incyte; Advisory/Consultancy: Merck; Advisory/Consultancy: Pfizer/EMD; Advisory/Consultancy: Serono; Advisory/Consultancy, Travel/Accommodation/Expenses: Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.